Angus Hodder

Angus Hodder

Auto-generated profile, based on publicly available information

Angus Hodder

Wellcome Sanger Institute, Hinxton, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2024 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
AHAngus Hodder
Angus Hodder
AMAvijeet K Mishra
Avijeet K Mishra
AEAmir Enshaei
Amir Enshaei
SBSusan Baird
Susan Baird
IEIsmail Elbeshlawi
Ismail Elbeshlawi
AVAjay Vora
Ajay Vora
PURPOSE: We tested whether blinatumomab (Blina) is effective as a toxicity-sparing alternative to first-line intensive chemotherapy in children and young persons (CYP) with B-ALL who were chemotherapy-intolerant or chemotherapy-resistant. METHODS: Data were collected for consecutive CYP (age 1-24 years) with Philadelphia chromosome–positive or Philadelphia chromosome–negative B-ALL who received Blina as first-line therapy. Blina was given as replacement for postremission intensive chemotherapy to patients with chemotherapy intolerance or resistance. Blina responders received further chemotherapy (Blin-CT) or first remission hematopoietic stem-cell transplant (Blin-HSCT) if indicated. Event-free survival (EFS) and overall survival (OS) of the Blin-CT group were compared with those of matched controls treated with standard chemotherapy in the UKALL 2003 trial. Events were defined as death, relapse, or secondary cancer. RESULTS: From February 2018 to February 2023, 105 patients were treated, of whom 85 were in the Blin-CT group and 20 were in the Blin-HSCT group. A majority of Blin-CT patients received Blina for chemotherapy intolerance (70 of 85, 82%), and the group had a higher-risk profile than unselected patients with B-ALL. Blina was well tolerated with only one patient having a grade 3/4–related toxicity event, and of the 60 patients who were minimal residual disease–positive pre-Blina, 58 of 60 (97%) responded. At a median follow-up of 22 months, the 2-year outcomes of the 80 matched Blin-CT group patients were similar to those of 192 controls (EFS, 95% [95% CI, 85 to 98] v 90% [95% CI, 65 to 93] and OS, 97% [95% CI, 86 to 99] v 94% [95% CI, 89 to 96]). Of the 20 in the HSCT group, three died because of transplant complications and two relapsed. CONCLUSION: Blina is safe and effective in first-line treatment of chemotherapy-intolerant CYP with ALL.

2 July 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AHAngus Hodder
Angus Hodder
SLSarah M. Leiter
Sarah M. Leiter
JKJonathan Kennedy
Jonathan Kennedy
DADilys Addy
Dilys Addy
MAMunaza Ahmed
Munaza Ahmed
SBSam Behjati
Sam Behjati
Clinical whole-genome sequencing (WGS) has been shown to deliver potential benefits to children with cancer and to alter treatment in high-risk patient groups. It remains unknown whether offering WGS to every child with suspected cancer can change patient management. We collected WGS variant calls and clinical and diagnostic information from 281 children (282 tumors) across two English units (n = 152 from a hematology center, n = 130 from a solid tumor center) where WGS had become a routine test. Our key finding was that variants uniquely attributable to WGS changed the management in ~7% (20 out of 282) of cases while providing additional disease-relevant findings, beyond standard-of-care molecular tests, in 108 instances for 83 (29%) cases. Furthermore, WGS faithfully reproduced every standard-of-care molecular test (n = 738) and revealed several previously unknown genomic features of childhood tumors. We show that WGS can be delivered as part of routine clinical care to children with suspected cancer and can change clinical management by delivering unexpected genomic insights. Our experience portrays WGS as a clinically impactful assay for routine practice, providing opportunities for assay consolidation and for delivery of molecularly informed patient care.

23 January 2025 in Cancer Discovery
Verified
Journal Article
Open access
TTTaryn D. Treger
Taryn D. Treger
JWJenny Wegert
Jenny Wegert
AWAnna Wenger
Anna Wenger
TCTim H.H. Coorens
Tim H.H. Coorens
RAReem Al-Saadi
Reem Al-Saadi
SBSam Behjati
Sam Behjati
Approximately 10% of children with cancer harbor a mutation in a predisposition gene. In children with the kidney cancer Wilms tumor, the prevalence is as high as 30%. Certain predispositions are associated with defined histological and clinical features, suggesting differences in tumorigenesis. To investigate this, we assembled a cohort of 137 children with Wilms tumor, of whom 71 had a pathogenic germline or mosaic variant. We examined 237 neoplasms (including two secondary leukemias), utilizing whole-genome sequencing, RNA sequencing, and genome-wide methylation, validating our findings in an independent cohort. Tumor development differed in children harboring a predisposition, depending on the variant gene and its developmental timing. Differences pervaded the repertoire of driver events, including high-risk mutations, the clonal architecture of normal kidneys, and the relatedness of neoplasms from the same individual. Our findings indicate that predisposition may preordain Wilms tumorigenesis, suggesting a variant-specific approach to managing children merits consideration. Significance: Tumors that arise in children with a cancer predisposition may develop through the same mutational pathways as sporadic tumors. We examined this question in the childhood kidney cancer, Wilms tumor. We found that certain predispositions dictate the genetic development of tumors, with clinical implications for these children. See related commentary by Brzezinski and Malkin, p. 258

14 July 2026 in Cancer Research
Verified
Journal Article
Open access
HWHolly J Whitfiled
Holly J Whitfiled
NANathaniel D. Anderson
Nathaniel D. Anderson
CBChristina Burke
Christina Burke
MKMarian J. Groot Koerkamp
Marian J. Groot Koerkamp
CPConor Parks
Conor Parks
SBSam Behjati
Sam Behjati
Somatic mutations often predict survival in childhood cancers, as exemplified in rhabdomyosarcoma (RMS), in which FOXO1 gene fusion status is a key prognostic feature. In this study, we examined single-cell transcriptomes and discovered that cancer cells of lethal disease converge on a common cell state with a shared transcriptional landscape, irrespective of fusion status. Nuclear transcriptomics, chromatin accessibility, spatial transcriptomics, perturbation studies, and previously published datasets validated the overarching high-risk cell state. The convergent cell state only partially overlapped with transcriptional effects of the FOXO1 fusion and unexpectedly exhibited neural features. Overall, these findings delineate a cell state of high-risk RMS cells that transcends conventional molecular and histologic boundaries, suggesting an overarching disease phenotype that could transform target discovery and inform clinical practice. Significance: Defining a convergent cell state of high-risk rhabdomyosarcoma that transcends existing histological and molecular features predictive of outcome provides biological insights into aggressive disease and uncovers potential biomarkers and therapeutic targets.

1 September 2026 in Blood Advances
Verified
Journal Article
Open access
MMMiguel Vieira Martins
Miguel Vieira Martins
AEAmir Enshaei
Amir Enshaei
YWYang Yang Wang
Yang Yang Wang
JGJude Gibson
Jude Gibson
JHJeremy P Hancock
Jeremy P Hancock
SSSujith Samarasinghe
Sujith Samarasinghe
Blinatumomab is increasingly incorporated into frontline therapy for B-cell acute lymphoblastic leukaemia (B-ALL), yet risk stratification remains based on chemotherapy-era factors that may not apply in the immunotherapy setting. We analysed a national cohort to define determinants of relapse following frontline blinatumomab. Children and young people (1-24 years) in the UK and Ireland diagnosed with B-ALL between 2018 and 2025 who were chemotherapy-intolerant or resistant received blinatumomab in place of selected components of the frontline chemotherapy backbone. Outcomes were analysed according to conventional prognostic variables, genetic features, and response to blinatumomab. Among 225 patients, 195 received chemotherapy following blinatumomab (Blin-CT) and 30 underwent first-remission HSCT. In the Blin-CT cohort, traditional risk factors, including age, white cell count, high-risk genetics, and pre-blinatumomab end-of-induction measurable residual disease (MRD) did not predict relapse. On univariable analysis, relapse risk was increased with detectable MRD after blinatumomab cycle 1 (C1-END; hazard ratio HZR 6.61, p<0.001), IKZF1plus (HZR 3.64, p=0.04), JAK-STAT abnormalities (HR 3.56, p=0.05), and DUX4 rearrangements (HZR 4.24, p=0.03). In multivariable modelling, C1-END MRD and IKZF1plus remained independently associated with relapse, whereas DUX4-rearranged cases were strongly associated with persistent MRD at C1-END. An integrated model incorporating C1-END MRD, IKZF1plus, and DUX4-r defined a high-risk subgroup (33%) with an 18% 2-year relapse rate versus 0% in remaining patients (bootstrapped HZR 12.82, p=0.001, C-index=0.81). Relapse following frontline blinatumomab is determined by early treatment response and genetic subtype rather than conventional chemotherapy-derived risk factors. These findings support immunotherapy-specific risk stratification to guide treatment intensity.

2 October 2026
Verified
Other
Open access
HWHolly J Whitfiled
Holly J Whitfiled
NANathaniel D. Anderson
Nathaniel D. Anderson
CBChristina Burke
Christina Burke
MKMarian J. Groot Koerkamp
Marian J. Groot Koerkamp
CPConor Parks
Conor Parks
SBSam Behjati
Sam Behjati
Multiomics profiling and clinical characterization of RMS across discovery and extension cohorts. A, A summary of previously published single-cell analyses of primary RMS. The current study (highlighted in blue) uniquely performed high-throughput single-cell transcriptomic profiling on fresh tissue, which preserves native gene expression states while minimizing artifacts caused by freezing. Sample numbers for our cohort only include samples that contain RMS cells. B, Heatmap depicts the application of sequencing assays across individual patients in the discovery cohort. Patients are grouped by clinical category: fusion-positive alveolar RMS (brown), fusion-negative with fatal outcome (red), and fusion-negative that have survived (purple). Each column represents an individual patient. The data indicates whether single-cell RNA-seq, WGS, and RNA-seq were performed. C, H&E-stained tumor sections from patients with fusion-negative RMS who died of their disease. These cases highlight histologic diversity and aggressive clinical behavior despite the absence of characteristic gene fusions.